Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

The psoriasis medication apremilast could hold promise in alcohol use disorder

By Brian Buntz | February 22, 2023

Apremilast

[Image courtesy of PubChem]

In two animal models, researchers found animals predisposed to mild-to-heavy alcohol use dropped their alcohol intake after taking apremilast, a phosphodiesterase 4 (PDE4) inhibitor. The scientists also tested apremilast in a Phase 2a study involving 51 subjects with moderate-to-severe alcohol use disorder. The subjects reduced their alcohol consumption from an average of five drinks per day to two.

PDE4 is tied to both alcohol and nicotine dependence.

“I’ve never seen anything like that before,” noted co-senior author and Oregon Health & Science University (OHSU) professor Angela Ozburn, in a news release.

The drug was also generally well tolerated in the study.

The researchers note that apremilast is better tolerated than than older PDE4 inhibitors such as rolipram and ibudilast, which can cause nausea and vomiting.

The Journal of Clinical Investigation published the research.

FDA first approved apremilast in 2014 as a treatment for psoriatic arthritis. Indications followed for plaque psoriasis and ulcers associated with Behçet’s disease.

While more research is required, the medication could be an “excellent candidate” for treating alcohol use disorder.

FDA has approved three treatments for AUD: disulfiram, naltrexone and acamprosate.

Disulfiram became the first therapy to treat AUD in 1949. The drug bolsters concentrations of ​​concentration of acetaldehyde, a toxic byproduct of alcohol.

Naltrexone, an opioid receptor antagonist, won approval for alcohol dependence in 1995.

FDA had approved another drug, acamprosate (Campral) for AUD in 2004.

The researchers found that apremilast lowered binge-like alcohol intake and behavioral measures of alcohol use disorder in a mouse model prone. They also found it was effective at curbing excessive drinking in models of stress-facilitated drinking and alcohol dependence.

The researchers hypothesized that the drug could be effective by bolstering neural activity in the nucleus accumbens, which plays a role in drug self-administration behaviors. The brain region is a common target in addiction and depression.

The company Clearmind Medicine (Nasdaq:CMND) is testing 5-methoxy-2-aminoindane (MEAI) as another potential therapy for AUD.


Filed Under: Psychiatric/psychotropic drugs
Tagged With: apremilast
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Muse Clinic: Innovating with Psychedelics and Neurotechnology
Can LSD break the 20-year drought in anxiety treatment?
MAPS
FDA rejection of MDMA and journal retractions jolt psychedelic therapy research
MDMA
Experts endorse MDMA-assisted therapy for PTSD amid FDA adcomm setback
depression sadness and loneliness concept art illustration of wo
Precision psychiatry: A data-driven approach to personalized depression treatment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE